Picture loading failed.

Anti-TNFSF4 therapeutic antibody (Pre-made Tavolimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tavolimab (MEDI 0562), a humanised IgG1κ monoclonal antibody agonist of OX40, was being developed by MedImmune for the treatment of solid tumours, including ovarian cancer.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-553-1mg 1mg 3090
GMP-Bios-ab-553-10mg 10mg 21890
GMP-Bios-ab-553-100mg 100mg 148000
GMP-Bios-ab-553-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-TNFSF4 therapeutic antibody (Pre-made Tavolimab biosimilar,Whole mAb)
INN Name Tavolimab
TargetTNFSF4
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2016
Year Recommended2018
CompaniesEuropean Network of Gynaecological Oncological Trial Groups;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedOvarian cancer;Solid tumours
Development Techna